However some authors disagree with this finding [18]. Prostate cancer cells with NE features escape programmed cell death [19]. Even under androgen deprivation, only 0.16% of NE tumour cells show apoptotic activity. This indicates that NE tumour cells represent an immortal pattern in prostate cancer. PSA is an important tool for detecting prostate cancer. However, it was reported

that the diagnostic role of serum PSA in assessing the treatment efficacy in patients with hormone-refractory disease did not correlate with changes in pain symptomatology and disease outcome [20]. Some authors reported that high levels of CgA allowed prognostic information independently from PSA [21], while others Osimertinib in vitro failed to show the same results

[6, 10, 11, 22, 23]. Neuroendocrine differentiation also appeared to be associated with the androgen-refractory state and a poor prognosis [6, 23–26]. It was reported that prostate cancer with a significant NE component is common in the advanced stage of the disease, especially in those patients who do not have elevated serum PSA levels [7, 25, 27, 28], but its diagnostic Midostaurin cost role in non metastatic disease is still a matter of debate [8, 29, 30]. We analyzed serum CgA levels in patients who were diagnosed with a prostate cancer before surgery. In our population 23.5% of all patients showed elevated pre-treatment circulating CgA levels. It is worthy to note that our population showed pre-treatment supra-normal CgA serum levels in the absence of distant metastases. In our series of patients serum CgA levels had no

significant association with PSA. According to other authors [25, 31], we found that CgA depicted a significant trend in association with high-grade disease. We did not observe any associations in our assessment of pathological stages. Conclusions According to our study, ChromograninA Resveratrol levels demonstrated a correlation with NE differentiation and possible aggressiveness of PC. This finding suggests that pre-operative circulating CgA determination could have a potential role in the clinical management of PC patients and could complement the PSA assay in an early selection of more aggressive PC such as those with NE features, particularly in those patients showing a higher Gleason score. References 1. Hvamstad T, Jordal A, Hekmat N, et al.: Neuroendocrine serum tumour markers in hormone-resistant prostate cancer. Eur Urol 2003, 44: 215–21.PubMedCrossRef 2. Smith DC, Dawson NA, Trump DL: Secondary hormonal manipulation. In Genitourinary oncology. 2nd edition. Philadelphia Lippincott Williams & Wilkins; 2000:855–76. 3. Bonkhoff H: Neuroendocrine cells in benign and malignant prostate tissue: morphogenesis, proliferation, and androgen receptor status. Prostate 1998, 8: 18–22,.CrossRef 4. Hansson J, Abrahamsson PA: Neuroendocrine pathogenesis in adenocarcinoma of the prostate.